International Journal of Clinical and Experimental Medicine Research

ISSN Print: 2575-7989 Downloads: 79947 Total View: 1342757
Frequency: quarterly ISSN Online: 2575-7970 CODEN: IJCEMH
Email: ijcemr@hillpublisher.com
Article http://dx.doi.org/10.26855/ijcemr.2020.10.025

Advances in Microecological Agents and Traditional Chinese Medicine in Reversing Cirrhosis

Juan Liu 1,*, Li Liu 2

1 Department of Medicine, Shaanxi University of Traditional Chinese Medicine (Xianyang 712000), China.

2 Department of Digestive Medicine, Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine (Xianyang 712000), China.

*Corresponding author: Juan Liu

Published: December 2,2020

Abstract

Liver cirrhosis (LC) is characterized by persistent, diffuse inflammation, fi-brosis and intrahepatic structure. Remodeling as a characteristic manifestation of chronic liver disease. The routine treatment is mainly antiviral, but its treatment method is relatively limited, and the therapeutic effect is not ideal. in recent years, a large number of clinical data have shown that the use of mi-croecological agents and traditional Chinese medicine treatment can inactivate hepatic stellate cells (HSC) and alleviate liver fibrosis, thus achieving the pos-sibility of liver cirrhosis reversal. In this paper, the research progress on the reversibility of cirrhosis in recent years is reviewed.

References

[1] Jung YK, Yim HJ. (2017). Reversal of liver cirrhosis: current evidence and expectations [J]. Korean J Intern Med. 2017; 32(2): 213-228. 

[2] Chang Hong, Guo Kai, Meng Hongyu, Liu Shumin. (n.d.). Advances in the study of the molecular mechanism of anti-hepatic fibrosis of hepatic stellate cells by the active components of traditional Chinese medicine [J]. Chinese Modern Chinese Medicine 19(01): 148-153.

[3] Xu Xiaoyuan, Ding Huiguo, Li Wengang, Xu Jinghang, Han Ying, Jia Jidong, Wei Lai, Duan Zhongping, Ling Huenqiang, Zhuang Hui. (2019). Guidelines for the diagnosis and treatment of [J]. Cirrhosis Journal of Clinical Hepatobiliary Diseases, 2019, 35(11): 2408-2425.

[4] Wang Guiqiang, Wang Fusheng, Zhuang Hui, Li Taisheng, Zheng Sujun, Zhao Hong, Duan Zhongping, Hou Jinlin, Jia Jidong, Xu Xiaoyuan, Cui Fuqiang, Wei Lai. (2019). Guidelines for the Prevention and Control of Chronic Hepatitis B (2019 Edition) [J]; and Chinese Journal of Medical Frontier (Electronic Edition), 2019, 11(12): 51-77.

[5] Chassaing B, Etienne-Mesmin L, Gewirtz AT. (2014). Microbiota-liver axis in hepatic disease [J]. Hepatology. 2014; 59(1): 328-339. 

[6] Lata J, Jurankova J, Kopacova M, et al. (2011). Probiotics in hepatology [J]. World J Gastroenterol. 2011; 17(24): 2890-2896. 

[7] Li Yanling, Zhang Huaihong, Zhai Yufeng. (2014). Effect of Probiotics on Hepatocyte Apoptosis in Cirrhotic Rats [J]. Chinese Journal of Gerontology, 2014, 34(03): 708-710.

[8] Chen Yihua. (n.d.). Application value of probiotics in the treatment of liver cirrhosis [J]. Northern Pharmacy 16(09): 113-114.

[9] Yu Shuxia. (2004). Effects of intestinal permeability and probiotics in cirrhotic patients [C]. and Chinese Society of Integrated Chinese and Western Medicine liver disease professional committee. Compilation of papers of the Thirteenth National Conference on Integrated Chinese and Western Medicine liver Disease. Chinese Society of Integrated Chinese and Western Medicine liver disease professional committee: China Society of Integrated Chinese and Western Medicine 2004:83-87.

[10] That Yan, Lou Xianzhi. (2019). Clinical efficacy of microbial agents combined with entecavir in the treatment of hepatitis B cirrhosis [J]. Journal of China Medical University, 2019, 49(2).

[11] Borrelli A, Bonelli P, Tuccillo F M, et al. (2018). Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches [J]. Redox Biology, 2018, 15: 467-479.

[12] Wang Rong, Xie Lingli, Song Mingyu. (2019). Advances in the study of the effects of gut microbiota on chronic liver disease [J\O].]. Chinese Journal of Integrated Chinese and Western Medicine digestion, 2019, 27(11), 879-882.

[13] Usami M, Miyoshi M, Yamashita H. (2015). Gut microbiota and host metabolism in liver cirrhosis. World J Gastroenterol. 2015; 21(41): 11597-11608. 

[14] Tripathi A, Debelius J, Brenner DA, et al. (2018). The gut-liver axis and the intersection with the microbiome [published cor-rection appears in Nat Rev Gastroenterol Hepatol. 2018 May 21]. Nat Rev Gastroenterol Hepatol. 2018, 15(7): 397-411. 

[15] Zhu Yun, Cheng Jia Dai, Wang Lifu, Yang Huiyin, Wang Zhongxia, Zhou Kun, Xiao Xiaohe, Li Yonggang. (n.d.). An overview of Chinese medicine in the treatment of drug-induced liver injury [J]. Journal of Hepatology with Integrated Chinese and Western Medicine 24(04): 254-256.

[16] Chang Hong, Guo Kai, Meng Hongyu, Liu Shumin. (n.d.). Advances in the study of the molecular mechanism of anti-hepatic fibrosis of hepatic stellate cells by the active components of traditional Chinese medicine [J]. Chinese Modern Chinese Medicine 19(01): 148-153.

[17] Wang Dianbing, Li Hengfei, Lu Dingbo. (2018). Clinical Effect of TCM Comprehensive Treatment Scheme on Compensatory Liver Cirrhosis [J]. World’s Latest Medical Information Digest, 2018, 18(86): 120-122.

[18] Peng, Chen Liang, Jiang Xiaoyan, Xing Yufeng, Jiang Mingjie, Tong Guangdong, Zhou Bridge. (n.d.). Experience of Professor Zhou Daqiao in the Treatment of Early Cirrhosis Journal of liver Disease with Integrated Chinese and Western Medicine 28(03): 183-185.

[19] Cai FF, Wu R, Song YN, et al. (2018). Yinchenhao Decoction Alleviates Liver Fibrosis by Regulating Bile Acid Metabolism and TGF-β/Smad/ERK Signalling Pathway [J]. Sci Rep. 2018; 8(1): 15367. 

[20] Cai FF, Bian YQ, Wu R, et al. (2019). Yinchenhao decoction suppresses rat liver fibrosis involved in an apoptosis regulation mechanism based on network pharmacology and transcriptomic analysis [J]. Biomed Pharmacother. 2019; 114: 108863.

[21] Li Musong, Tian Yanhong, Zhao Yuqian, Yang Huixuan. (n.d.). Advances in Clinical Research of Yinchenhao Decoction [J]; and Chinese folk medicine 27(16): 51-53.

[22] Zhu Yun, Cheng Jia Dai, Wang Lifu, Yang Huiyin, Wang Zhongxia, Zhou Kun, Xiao Xiaohe, Li Yonggang. (n.d.). An overview of Chinese medicine in the treatment of drug-induced liver injury [J]. Journal of Hepatology with Integrated Chinese and Western Medicine 24(04): 254-256.

[23] Hu Yanwu, Liu Kai, Yan Mengtong, Wang Lei, Liu Mingdong, Yu Junlin, Wu Zijing. (n.d.). Effect of stem extract of Schisandra chinensis on liver fibrosis in rats [J]. Its mechanism Chinese Journal of Experimental prescriptions 22(17): 122-125.

[24] Yu Huanghe, Li Xin, Yang Zhen, Lin Yi, Yan Jianye, Wang Yuanqing, Zeng Rong, Wang Wei, Cai Xiong. (n.d.). Advances in Pharmacological Action of Schisandra chinensis [J]. Universal Chinese Medicine 12(07): 1133-1138.

[25] Chen Q, Zhang H, Cao Y, et al. (2017). Schisandrin B attenuates CCl4-induced liver fibrosis in rats by regulation of Nrf2-ARE and TGF-β/Smad signaling pathways [J]. Drug Des Devel Ther. 2017; 11: 2179-2191.

[26] Lin Hui, Mei Quanxi, Kong Xianglian, Wang Yunting, Chen Zongliang. (2011). Clinical Application and Mechanism of Hedyotis diffusa in the Treatment of Hepatic Disease [J]. A Asia Pacific Traditional Medicine, 2011, 7(10): 173-175.

[27] Cao Haifang, Zu Hongmei, Peng Junning, Wang Hude, Han Yun, Lu Qinghua. (n.d.). Effect of Salvia miltiorrhiza combined with tenofovirate on liver protection in hepatitis B cirrhosis [J]. Chinese Journal of traditional Chinese Medicine 36(07): 1679-1682.

[28] Lu Zhenzhen, Su Qijian, Li Xuan, Fu Linchun. (2015). Comparison of efficacy and drug resistance analysis of high-efficiency antiretroviral therapy with tenofovir or zidovudine [J]. Journal of Applied Medicine, 2015, 31(09): 1475-1478.

[29] Xia Hua. (2017). Effects of Compound Danshen Tablets Combined with Nucleoside Antiviral Drugs on Fibrosis Indexes in Hepatitis B Cirrhosis Patients [J]. Chinese convalescent medicine, 2017, 26(08): 865-866.

[30] Jiang Hongwei. (2007). 30 Cases of Hepatitis Cirrhosis Treated by Single Flavor [J]. Biejia Clinical Medicine, 2007(06): 93-94.

[31] Sun Zhenliang, Wu Zhe, Guixiangping, Tian Lingyun, Li Xianpeng. (2019). Effect of Compound Biejia Softgan Tablets on Liver Fibrosis Rats and Journal of Yunnan College of traditional Chinese Medicine, 2019, 42(01): 30-58.

[32] Huangfu Yanlin, Wu Huikun. (2019). Advances in the Treatment of Cirrhosis with Chinese Medicine [J]. Journal of Liaoning University of Traditional Chinese Medicine, 2019, 21(07), 221-224.

[33] Lin LJ, Chen GF, Gu HT, et al. (2014). Performance of Fibro Scan in evaluating the curative effects of tradition Chinese medicine on liver fibrosis [J]. Chin J Hepatol, 2014, 22(2): 113-117. 

[34] Li Aizhi, Feng Xianni, Zhang Chunju, et al. (2012). Treatment of 25 cases of chronic hepatitis B with adefoviride [J]. Chronic hepatitis B early cirrhosis Traditional Chinese Medicine Research, 2012, 25(3): 28-30.

[35] Gu Shaoyu. (2013). Clinical Observation on 72 Cases of Early Liver Cirrhosis Treated by Self-Drafting Qing Liver Decoction [J].] Inner Mongolia Chinese Medicine, 2013, 32(2): 4.

[36] Acharya C, Sahingur SE, Bajaj JS. (2017). Microbiota, cirrhosis, and the emerging oral-gut-liver axis. JCI Insight. 2017; 2(19): e94416. Published 2017 Oct 5.

How to cite this paper

Advances in Microecological Agents and Traditional Chinese Medicine in Reversing Cirrhosis

How to cite this paper: Juan Liu, Li Liu. (2020) Advances in Microecological Agents and Traditional Chinese Medicine in Reversing Cirrhosis. International Journal of Clinical and Experimental Medicine Research, 4(4), 272-277.

DOI: http://dx.doi.org/10.26855/ijcemr.2020.10.025